Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...